Our Take
A second indication for an existing drug is regulatory progress, not a clinical advance; the ECLIPSE trial met its primary endpoint but the competitive position against other acute migraine agents remains unstated.
Why it matters
Migraine affects millions in Europe and causes significant functional impairment. For AbbVie, this expands Aquipta's commercial footprint within the EU market where it already holds preventive approval.
Do this week
Neurology and pain management practices in the EU: audit your current acute migraine protocols to determine whether oral CGRP antagonists fit your patient population before Aquipta becomes formulary standard.
EC approves Aquipta for acute migraine
AbbVie received European Commission approval for Aquipta (atogepant), an oral CGRP receptor antagonist, for acute treatment of migraine in adults with or without aura. This marks the second indication for the drug in the EU; it was previously approved as a once-daily preventive for adults experiencing four or more migraine days per month.
The approval rests on Phase III ECLIPSE trial data. The randomised, 24-week, placebo-controlled study enrolled 1,328 adults across 149 sites in China, the EU, Japan, South Korea, Taiwan, and the UK. Participants had a history of two to eight moderate to severe migraine attacks per month.
The trial met its primary endpoint: Aquipta 60mg achieved pain freedom at two hours post-treatment more often than placebo on the first attack. Secondary endpoints showed relief of most bothersome symptoms and reduced rescue medication use. Adverse events were primarily nasopharyngitis and upper respiratory tract infections (per company-reported data).
AbbVie's chief scientific officer Roopal Thakkar stated the approval allows the company to address acute migraine needs in Europe alongside its preventive portfolio.
Regulatory milestone, not category shift
AbbVie now holds both acute and preventive approvals for a single agent across the EU, which simplifies prescribing and patient communication. Migraine causes significant cognitive impairment, photophobia, phonophobia, and nausea; two-hour pain freedom is a meaningful clinical endpoint for functional recovery.
The gap: no independent head-to-head data against other acute migraine treatments (triptans, ditans, or other CGRP antagonists) appears in the source material. The ECLIPSE trial compared Aquipta to placebo only. Without comparative benchmarking, the clinical advantage relative to existing acute treatments remains opaque to practitioners evaluating formulary position.
Audit your acute migraine algorithm
If you treat episodic or chronic migraine in the EU, compare Aquipta's pharmacology (oral, 60mg, two-hour pain freedom in trial) against your current first-line acute agents. Document whether oral onset, once-daily preventive option (if patients meet that criterion), and CGRP mechanism offer advantage over existing triptans or ditans for your patient cohort. Request head-to-head efficacy data from AbbVie if formulary consideration is pending; absence of independent comparators should inform your decision weight.